

consisting of citrated plasma and a citrate-containing plasma fraction, wherein (I) said medicament is substantially free from undesired metals selected from the group consisting of aluminum, cadmium, zinc, lead and iron, and (II) said medicament does not take up any undesired metals when stored in metal-containing containers, wherein said method comprises exchanging citrate and optionally citrate-bound metals in a plasma-protein-containing solution for one selected from the group consisting of a water-soluble monocarboxylate, a water-soluble dicarboxylate, a monocarboxylic acid and a dicarboxylic acid, wherein the exchanging occurs under non-precipitating conditions,

recovering at least one plasma protein, and

finishing said medicament.

15. (Twice amended) The method as set forth in claim 14, wherein said at least one plasma protein recovered is selected from the group consisting of the factors of coagulation, factors of fibrinolysis, immunoglobulins, glycoproteins and albumin.

16. (Three Times Amended) The method as set forth in claim 14, wherein] monocarboxylate, dicarboxylate, monocarboxylic acid or dicarboxylic acid has 2 to 20 carbon atoms.

17. (Twice amended) The method as set forth in claim 14, wherein said exchanging of said citrate and optionally of said citrate-bound metals is performed using a t least one substance selected from the group consisting of a caprylate and a tartrate.

18. (Twice amended) The method as set forth in claim 14, wherein said exchanging of said citrate and optionally of said citrate-bound metals is performed using a monocarboxylic or dicarboxylic acid having 2 to 4 carbon atoms.

20. (Twice amended) The method as set forth in claim 14, wherein said exchanging of said citrate and optionally of said citrate-bound metals is performed during one of a diafiltration, ultrafiltration, gel permeation chromatography and a chromatographic separation method.

21. (Twice amended) The method as set forth in claim 14, further comprising subjecting said plasma-protein-containing solution to at least one of a purification and a concentration procedure before said exchanging of said citrate and optionally of said citrate-bound metals.

22. (Twice amended) The method as set forth in claim 14, further comprising subjecting said plasma-protein-containing solution to a treatment for virus inactivation.

23. (Twice amended) The method as set forth in claim 22, wherein said treatment for virus inactivation is performed before said exchanging of said citrate and optionally of said citrate-bound metals.

24. (Twice amended) The method as set forth in claim 22, wherein said treatment for virus inactivation is performed after said exchanging of said citrate and optionally of said citrate-bound metals.

25. (Twice amended) The method as set forth in claim 22, wherein said treatment for virus inactivation is performed before and after said exchanging of said citrate and optionally of said citrate-bound metals.

26. (Amended) The method as set forth in claim 22, wherein said treatment for virus-inactivation is a heat-treatment.

27. (Twice amended) The method as set forth in claim 22, wherein said treatment for virus inactivation is performed immediately after said recovering of at least one plasma protein in the presence of the monocarboxylate or dicarboxylate.

28. (Twice amended) The method as set forth in claim 14, wherein the finishing of said medicament is performed using only citrate-free components.

D7
cont.

29. (Twice amended) The method as set forth in claim 14, wherein said exchanging of said citrate and optionally of said citrate-bound metals is performed in the presence of sodium chloride.

D8

30. (Amended) The method as set forth in claim 29, wherein said sodium chloride is an at least 4% by weight sodium chloride solution.

D9

31. (Twice amended) A plasma-protein-containing medicament ^{use of,} using as a starting material one selected from the group consisting of citrate plasma and a citrate-containing plasma fraction, wherein the medicament is (I) substantially free from undesired metals selected from the group consisting of aluminum, cadmium, zinc, lead and iron, and (II) said medicament does not take up any undesired metals when stored in metal-containing containers, wherein the medicament is obtained by

exchanging citrate and optionally citrate-bound metals in a plasma-protein-containing solution for one selected from the group consisting of a water-soluble monocarboxylate, a water-soluble dicarboxylate, a water-soluble monocarboxylic acid and a water-soluble dicarboxylic acid, wherein the exchanging occurs under non-precipitating conditions,

recovering at least one plasma protein, and

finishing said medicament, wherein

said medicament has a content of undesired metals of less than 100 µg/l.

D¹⁰
33. (Amended) The plasma-protein-containing medicament as set forth in claim 31, wherein said content of undesired metals is less than 10 $\mu\text{g/l}$. *mat*

D¹¹
34. (Twice amended) The plasma-protein-containing medicament as set forth in claim 31, wherein said content of undesired metals is less than 200 ng/l. *mat*

35. (New) The method according to claim 14, wherein the medicament has a content of undesired metals of less than 100 $\mu\text{g/l}$.

D¹²
36. (New) The method according to claim 35, wherein the medicament has a content of undesired metals of less than 10 $\mu\text{g/l}$. *mat*

37. (New) The method according to claim 36, wherein the medicament has a content of undesired metals of less than 200 ng/l.